Key result
Metabolic syndrome linked to higher cardiovascular risk and lower adiponectin in middle-aged obese men.
Why the study?
To determine the impact of metabolic syndrome on cardiovascular disease risk in obese men by assessing adiponectin levels, cardio-ankle vascular index, and 10-year risk of atherosclerotic cardiovascular disease, and evaluate their potential as CVD predictors.
Does metabolic syndrome impact adiponectin levels, CAVI, and cardiovascular risk in middle-aged obese men?
Cross-Sectional (n=82)
Does metabolic syndrome impact adiponectin levels, CAVI, and cardiovascular risk in middle-aged obese men?
In middle-aged obese men, metabolic syndrome is associated with higher cardiovascular risk scores and lower adiponectin levels, while CAVI serves as an independent predictor of CVD risk in this population.
Should not yet alter CVD risk assessment in obese men; hypothesis-generating for adiponectin and CAVI as predictors.
This study aimed to determine the impact of metabolic syndrome (MetS) on cardiovascular disease (CVD) risk in obese men by assessing adiponectin levels, cardio-ankle vascular index (CAVI), and the 10-year risk of atherosclerotic cardiovascular disease using the Thai cardiovascular risk score (TCVRS), and evaluated whether CAVI and adiponectin could serve as predictors for CVD. Among 82 middle-aged obese men, 70.7 % had MetS, 56.1 % had hypoadiponectinemia, 20.7 % were classified as having a high CAVI (>8), and 15.9 % were considered at high cardiovascular risk (TCVRS ≥20 %). Participants in the MetS group had a higher CVD risk, as evidenced by significantly higher TCVRS and lower adiponectin compared to the non-MetS group, though CAVI did not differ significantly. Among the components of MetS, high triglyceride and low HDL-cholesterol levels affected adiponectin levels, while high fasting plasma glucose levels impacted CAVI values, which was supported by Spearman correlation analysis. Additionally, CAVI positively correlated with TCVRS and was identified as an independent predictor of CVD risk in both the total and MetS groups. Conversely, adiponectin exhibited an inverse correlation and was an independent predictor in the non-MetS group. Importantly, subgroup analysis indicated that participants with higher CAVI had a greater CVD risk compared to those with normal CAVI levels. Notably, participants with high CAVI who did not have hypoadiponectinemia exhibited the highest TCVRS, with over half classified as being at high cardiovascular risk. • In this study, metabolic syndrome (MetS) showed no association with high CAVI values. • Among MetS components, TG and HDL affected adiponectin levels, while FPG impacted CAVI values. • CAVI values showed an inverse trend with weight and BMI in the MetS group but a positive trend in the non-MetS group. • CAVI could be an independent predictor for CVD in the MetS group, while adiponectin was for the non-MetS group. • The high CAVI without hypoadiponectinemia group had the highest CVD risk score.
No takes yet. Share an insight, caveat, or question.
Nutmakul et al. (2025) conducted a cross-sectional in Obesity and Metabolic Syndrome (n=82). Metabolic syndrome vs. No metabolic syndrome was evaluated on Cardiovascular disease risk (TCVRS), adiponectin levels, and CAVI. Among 82 middle-aged obese men, 70.7% had metabolic syndrome, which was associated with higher cardiovascular risk and lower adiponectin compared to those without metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: